Fullscript Protocols

Aging and Longevity Support

Upload template
Woman ordering supplements on her laptop
Protocols Fullscript Protocols
Aging and Longevity Support

Protocol development in integrative medicine is not typically a simple process. Individuals require individualized care, and what works for one patient may not work for another.

To establish these protocols, we first developed a Rating Scale that could be used to discern the rigor of evidence supporting a specific nutrient’s therapeutic effect.

The following protocols were developed using only B through D-quality evidence.

RDBPC human trials
2+ studies and/or 1 study with 50 + subjects
RDBPC human trials
1 study
Non-RDBPC human or In-vivo animal trials


Multivitamin formulation, minimum 8 weeks1

  • Multivitamin use was associated with longer telomere length in women aged 35 to 742
  • Multivitamins containing a combination of minerals and herbs were shown to decrease perceived mental stress in an elderly population several hours after intake4
  • Multivitamin intake in elderly women was associated with an increase in inhibitory neural processes, which translates into an improvement in neural efficiency during memory retrieval3
  • Multivitamins were shown to improve alertness and negative mood symptoms in men aged 50 to 69 years old1
Multivitamin in the Fullscript catalog.

Omega-3 fatty acids

1.25-2.5g of Omega-3 PUFA, total per day, minimum 8 weeks5,6,7

  • Omega-3 PUFA has been shown to increase telomerase levels and lengths5,6
  • Omega-3 PUFAs have shown to reduce IL-1β, TNF-α, and IL-6, factors that contribute to the effects of inflammaging7

For a more detailed review of Omega 3 fatty acids, refer to the Fullscript reference sheet: https://fullscript.com/hcp/fish-oil

Omega 3 fatty acids in the Fullscript catalog.

New and upcoming research:

Astragalus membracanus

10-50mg of TA-65, total per day, minimum 12 months8

  • Decline in the percentage of senescent cytotoxic T cells (CD8+ and CD28-) and natural killer cells were observed in seropositive patients9
  • TA-65 has been demonstrated a clinically significant effect in lengthening telomerase and decreasing the percentage of short telomerase8,9
Astragalus membracanus in the Fullscript catalog.


The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

Upload template